Enanta Pharmaceuticals
ENTA
148 hedge funds and large institutions have $956M invested in Enanta Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 54 increasing their positions, 57 reducing their positions, and 15 closing their positions.
18% more capital invested
Capital invested by funds: $811M → $956M (+$145M)
0.41% more ownership
Funds ownership: 95.93% → 96.34% (+0.41%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 57
2% less funds holding
Funds holding: 151 → 148 (-3)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
76% less call options, than puts
Call options by funds: $1.29M | Put options by funds: $5.39M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$20.3M |
| 2 |
BlackRock
New York
|
+$16.1M |
| 3 |
AC
Armistice Capital
New York
|
+$14.6M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$11M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$11.9M |
| 2 |
First Manhattan
New York
|
-$10M |
| 3 |
Millennium Management
New York
|
-$7.63M |
| 4 |
Man Group
London,
United Kingdom
|
-$7.46M |
| 5 |
Renaissance Technologies
New York
|
-$6.67M |
ENTA Hedge Fund Activity: Q1 2021 in Review
148 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2021, worth a combined $956M — up 18% from $811M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ENTA and 13 opened new positions — a net loss of 2 holders — while 57 trimmed existing stakes and 54 added.
The largest buyer was Northern Trust, adding an estimated $20.3M. The largest seller was Invesco, cutting an estimated $11.9M.
- 148 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2021, down from 151 in Q4 2020.
- Funds reported $956M of Enanta Pharmaceuticals stock for Q1 2021, up 18% quarter-over-quarter.
- 13 funds opened new Enanta Pharmaceuticals positions in Q1 2021 and 15 closed out, a net change of -2 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2021 was Northern Trust, an estimated $20.3M added.
- The largest Enanta Pharmaceuticals seller in Q1 2021 was Invesco, an estimated $11.9M sold.
Based on aggregated 13F filings for Q1 2021.